In vitro and in vivo killing of AML using tetravalent bispecific CD33/CD3 TandAbs
May 30, 2015
Acute myeloid leukemia (AML) is the most common form of adult leukemia. Since this disease progresses rapidly, “off the shelf” treatments are highly desirable. CD33 is found on AML blasts in most AML patients, and on leukemic stem cells in some, making it a promising target for AML therapies.
Development Of A Bispecific Tetravalent CD33/CD3 TandAb For The Treatment of AML
May 31, 2015
Acute myeloid leukemia (AML) is a hematologic malignancy in need of new and effective treatment options. Immunotherapeutics may provide a much needed alternative to cytotoxic chemotherapy that remains the standard treatment for this disease.
Construction and Characterization of Novel CD33/CD3 Tandem Diabodies (TandAbs®) for the Treatment of Acute Myeloid Leukemia (AML)
May 31, 2015
CD33 has been validated as target for antibody- based therapy through randomized studies with the CD33 antibody-drug conjugate gemtuzumab ozogamicin (GO), but currently CD33-targeted therapeutics are ineffective in many patients.
Amphivena Therapeutics Presents Positive Data on Novel Acute Myeloid Leukemia (AML) Immunotherapy at 2015 ASCO Annual Meeting
June 1, 2015
Positive Preclinical Study Results Demonstrate Potent and Specific Anti-AML Activity for Amphivena’s Proprietary T-cell Redirecting Bispecific CD33/CD3-Targeting Antibodies; AMV-564 Being Advanced into Clinical Development for Treatment of AML
AMPHIVENA THERAPEUTICS TO PRESENT DATA ON NOVEL CANCER IMMUNOTHERAPY AT 2015 ASCO ANNUAL MEETING
May 25, 2015
Positive Preclinical Study Results Support Advancement of Amphivena’s Proprietary Bispecific CD33/CD3-
Targeting Therapeutic Candidate into Clinical Development for Treatment of Acute Myeloid Leukemia (AML)
Amphivena Therpeutics Achieves Development Milestones Under Agreement With Janssen
April 7, 2015
SAN FRANCISCO, CA, April 7, 2015 — Amphivena Therapeutics, Inc., a developer of cancer immunotherapeutics, today announced the achievement of the first and second milestones under the terms of its agreement with Janssen Biotech, Inc. Amphivena and Janssen have selected a clinical candidate against an undisclosed tumor antigen for further development in hematologic malignancies. The milestones triggered the release of payments to Amphivena. The financial details were not disclosed. The agreement was facilitated by Johnson & Johnson Innovation.